Allergan’s Inamed Purchase Delayed; Reloxin Will Go To Medicis
This article was originally published in The Gray Sheet
Executive Summary
Allergan was forced to push back its $3.2 bil. purchase of Inamed after failing to obtain the requisite amount of stock from Inamed shareholders
You may also be interested in...
Medicis reveals purchase price
Thanks to the close of the Allergan/Inamed deal, Medicis' exclusive license of Ipsen's Reloxin botulinum toxin type A product goes through for $90.1 mil. in cash, plus nearly $103 mil. in milestone payments. Ipsen will manufacture the product and Medicis will have the right to develop and distribute the product exclusively until 2019. Inamed previously had rights to the product but divested them in order to avoid antitrust snags due to Allergan's existing Botox product (1"The Gray Sheet" March 20, 2006, p. 17)...
Medicis reveals purchase price
Thanks to the close of the Allergan/Inamed deal, Medicis' exclusive license of Ipsen's Reloxin botulinum toxin type A product goes through for $90.1 mil. in cash, plus nearly $103 mil. in milestone payments. Ipsen will manufacture the product and Medicis will have the right to develop and distribute the product exclusively until 2019. Inamed previously had rights to the product but divested them in order to avoid antitrust snags due to Allergan's existing Botox product (1"The Gray Sheet" March 20, 2006, p. 17)...
Allergan-Inamed Deal OK’d By Federal Trade Commission; Closure Imminent
Allergan's $3.2 bil. acquisition of aesthetics firm Inamed was set to close March 10, following Federal Trade Commission approval of the deal on March 8